MedTrace Logo

To Assess the Safety, Tolerability and Pharmacokinetics of ACH-000029 in Healthy Subjects

NCT05363839 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2023-04-27

No results posted yet for this study

Summary

Randomized single ascending dose placebo controlled treatment of ACH-000029 administered orally via capsule in healthy volunteers.

Conditions

  • Healthy Volunteers

Interventions

DRUG

ACH-000029

ACH-000029 will be administered orally via a capsule.

DRUG

Placebo

Placebo will be administered orally via a capsule.

Sponsors & Collaborators

  • Otsuka Pharmaceutical Development & Commercialization, Inc.

    collaborator INDUSTRY

  • Syneos Health

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-05-06
Primary Completion
2022-11-02
Completion
2022-11-02

Countries

  • Australia

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05363839 on ClinicalTrials.gov